Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Botulinum Toxin type A injection Versus Lidocaine Injection for Myofascial Pain Involving upper Trapezius

´ëÇѱ¸°­³»°úÇÐȸÁö 2005³â 30±Ç 3È£ p.345 ~ 351
¼Ò¼Ó »ó¼¼Á¤º¸
¾È¼º¿ì ¹ÚÀºÈñ/±è¹ÌÀº

Abstract

±Ù¸·µ¿Åë(myofascial pain syndrome, MPS)Àº ±Ù¸·¹ßÅëÁ¡¿¡ ÀÇÇØ ¾ß±âµÇ´Â Áö°¢, ¿îµ¿ ¹× ÀÚÀ²½Å°æ°èÀÇ Áõ»óÀ¸·Î ¹ßÅëÁ¡ÀÌ ÀڱصǸé ÀÌȯºÎ¿¡ µ¿ÅëÀ» ¹ß»ýÇÒ »Ó ¾Æ´Ï¶ó ¿¬°üÅë, ¿¬°ü¾ÐÅë, ¿îµ¿½Å°æÀå¾Ö, ÀÚÀ²½Å°æ¹ÝÀÀÀ» ¾ß±âÇÒ ¼ö ÀÖ´Ù. º» ¿¬±¸´Â ±Ù¸·µ¿ÅëÀÇ ´Ù¾çÇÑ Ä¡·á¹ý Áß¿¡¼­ botulinum toxin type A(BTX-A)ÀÇ ÁÖ»çÀÇ È¿°ú¸¦ ±¹¼Ò¸¶ÃëÁ¦ÀÎ lidocaineÀÇ ÁÖ»çÈ¿°ú¿Í ºñ±³ÇÏ¿´´Ù. »óºÎ ½Â¸ð±Ù¿¡ 6°³¿ù ÀÌ»ó È°µ¿¼º ¹ßÅëÁ¡À» °¡Áø 21¸íÀÇ È¯ÀÚ¸¦ ¼±Á¤ÇÑ ´ÙÀ½, ¹«ÀÛÀ§·Î µÎ ±ºÀ¸·Î ³ª´©¾î ÇÑ ±º(BTX-A Áֻ籺, n=12)¿¡´Â ¹ßÅëÁ¡¿¡ BTX-A(15 unit of Botox¢ç / 0.3 ml per trigger point (TrP))¸¦ ÁÖ»çÇÏ°í ´Ù¸¥ ±º(lidocaine Áֻ籺, n=9)¿¡´Â 0.5% lidocaine (0.3 ml/TrP)¸¦ ÁÖ»çÇÏ¿´´Ù. µÎ ±º ¸ðµÎ ÁÖ»ç´Â 1 ȸ¸¸ ½ÃÇàÇÏ¿´À¸¸ç ¿îµ¿¿ä¹ýÀ̳ª ¹°¸®Ä¡·á ¹× ¾à¹°Ä¡·á´Â ½ÃÇàÇÏÁö ¾Ê¾Ò´Ù. ÁÖ»ç ÈÄ µ¿ÅëÀÇ º¯È­¸¦ °üÂûÇϱâ À§ÇÏ¿© ÁÖ»ç Àü ¹× ÁÖ»ç ÈÄ 2 ÁÖ, 4 ÁÖ, 6 ÁÖ, 8 ÁÖ¿¡ ÁÖ°üÀû µ¿ÅëôµµÀÎ VAS¿Í ¾Ð·ÂÅë°¢¿ªÄ¡(PPT)¸¦ ÃøÁ¤ÇÏ¿´À¸¸ç ½ÇÇèÀº ÀÌÁ߸ͰËÀ¸·Î ½ÃÇàµÇ¾ú´Ù.
½ÇÇè°á°ú, BTX-A Áֻ籺Àº ÁÖ»ç ÈÄ 8 ÁÖÀÇ ½Ã°£ÀÌ °æ°úµÇ´Â µ¿¾È VAS°¡ Áö¼ÓÀûÀ¸·Î °¨¼ÒÇÏ¿´À¸¸ç PPT´Â Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÏ¿´À¸³ª lidocaine Áֻ籺¿¡¼­´Â VASÀÇ °¨¼Ò¸¸ÀÌ °üÂûµÇ¾ú´Ù. Áï, ÁÖ°üÀûÀÎ µ¿Åëôµµ¿¡ À־´Â BTX-A Áֻ籺°ú lidocaine Áֻ籺 »çÀÌ¿¡ À¯ÀÇÇÑ Åë°èÇÐÀû Â÷ÀÌ°¡ ³ªÅ¸³ªÁö ¾Ê°í(p=0.347), µÎ ±º ¸ðµÎ ½Ã°£ °æ°ú¿¡ µû¶ó µ¿ÅëÀÌ °¨¼ÒÇÏ´Â ¾ç»óÀ» º¸¿©ÁÖ¾ú´Ù. ±×·¯³ª PPTÀÇ °æ¿ì¿¡´Â BTX-A Áֻ籺¿¡¼­¸¸ °¨¼ÒÇÏ¿© µÎ ±º »çÀÌ¿¡ À¯ÀÇÇÑ Åë°èÇÐÀû Â÷ÀÌ°¡ °üÂûµÇ¾ú´Ù(p=0.000). º» ¿¬±¸ÀÇ °á°ú¿¡ µû¸£¸é »óºÎ½Â¸ð±Ù ¹ßÅëÁ¡¿¡ ´ëÇÑ BTX-A ÁÖ»ç´Â È¿°úÀûÀÌ°í ½Å·ÚÇÒ ¸¸ÇÑ Ä¡·á¹ýÀ̶ó°í »ý°¢µÈ´Ù.

The purpose of this double-blind study was to evaluate clinical effects of botulinum toxin type A (BTX-A) injection on myofascial pain syndrome (MPS) involving upper trapezius and compare with those of lidocaine injection. 21 patients presenting with active TrP1 and/or TrP2 in the upper trapezius over 6 months were selected for this study. The subjects were randomly divided into two groups; one group injected with BTX-A (15 unit¤·of Botox¢ç / 0.3 ml per trigger point (TrP)) and the other group injected with 0.5% lidocaine (0.3 ml /TrP). The clinical effects were evaluated by VAS and PPT at baseline, 2, 4, 6 and 8 weeks after treatment.
BTX-A group showed persistent decrease of VAS values and increase of PPT values following treatment. While there was no significant difference in VAS values between BTX-A and lidocaine groups (p=0.347), there was significant difference in PPT values after treatment between two groups (p=0.000). The subjects received BTX-A showed noticeable improvement in PPT values after treatment, suggesting more reliable effect of BTX-A injection compared with lidocaine injection. The results of this study support that the direct injection of BTX-A to a TrP is an effective and safe treatment for MPS involving upper trapezius.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI